Articles By Estel Grace Masangkay
-
AstraZeneca, Amgen Trumpet Positive Phase 3 Results For Brodalumab
11/14/2014
AstraZeneca and its partner Amgen announced positive results from the second pivotal Phase 3 trial of brodalumab in moderate-to-severe plaque psoriasis.
-
Sanofi Posts Positive Results For Asthma Drug Dupilumab
11/13/2014
Sanofi and its partner Regeneron Pharmaceuticals reported positive results from the Phase 2B trial of dupilumab in patients with unmanaged moderate-to-severe asthma.
-
Merck Posts Phase 2 Data For Grazoprevir/Elbasvir In HCV
11/13/2014
Merck announced that it presented results from the Phase 2 trial of combo therapy grazoprevir/elbasvir with or without ribavirin (RBV) in patients with Hepatitis C virus (HCV) genotype 1 infection.
-
Lilly Launches Trulicity For Diabetes In U.S.
11/13/2014
Eli Lilly & Co.announced that its recently approved diabetes drug Trulicity (dulaglutide) is now available in pharmacies across the U.S.
-
Novartis To Present Phase 3 Data For Secukinumab At ACR
11/12/2014
Novartis reported that it will present data from four Phase 3 trials of secukinumab (AIN457) investigating the drug in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) at the American College of Rheumatology (ACR) Congress taking place this month.
-
Merck Presents Anti-PD-1 Keytruda Data In 3 Cancers
11/12/2014
Merck announced that it will present new data for its anti-PD-1 therapy Keytruda (pembrolizumab) in advanced melanoma versus chemotherapy, in relapsed/refractory classical Hodgkin Lymphoma (cHL), and advanced triple negative breast cancer (TNBC).
-
Merrimack Pharma Begins Phase 1 Trial Of Brain Cancer Drug
11/10/2014
Biopharmaceutical company Merrimack Pharma announced that its Phase 1 clinical study of MM-398 (nanoliposomal irinotecan injection) has begun with the enrollment of the first patient for the trial.
-
MedImmune Acquires Definiens, Biomarker Tool Technology
11/7/2014
AstraZeneca announced that its global biologics R&D arm MedImmune has acquired the Germany-based firm Definiens, which specializes in imaging and data analysis technology.
-
Genzyme Launches Phase 2 Vatelizumab Trial In RRMS
11/7/2014
Sanofi company Genzyme announced that it has kicked off the Phase 2 clinical trial of its investigational infusion therapy vatelizumab in patients with relapsing remitting multiple sclerosis (RRMS).
-
D-Pharm Posts Phase 2 Trial Results For THR-18 In Stroke
11/6/2014
D-Pharm, a clinical stage biopharmaceutical company focused on developing treatments for CNS disorders, posted the first safety results from its Phase 2 clinical study of its drug THR-18 in acute ischemic stroke (AIS) patients treated with tissue plasminogen activator (tPA).